SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABSW
SAB Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.60+0.07 (+2.77%)
Close on Oct 19, 2026
- Market cap
- $207.36M
- P/E (TTM)
- –
- Dividend yield
- –
SAB Biotherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|
| Grant [Member] | $23.90M | $60.88M | $55.24M | 100.0% | -60.7% |
| Grant Revenue [Member] | – | $60.88M | $55.24M | – | – |
By region
From the segment and revenue-disaggregation notes of SAB Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.